Skip to main content

Author: Louise Stanley

BHP announces exciting new role for its outgoing Chair

Birmingham Health Partners (BHP) has announced its Chair, Jonathan Pearson, will be stepping down at the end of his two-year term in September 2025, following his appointment as Chair of BHP member Health Innovation West Midlands (HIWM).

A highly experienced health business leader, Jonathan has chaired BHP for the past 18 months and has overseen significant progress and growth within the partnership – most notably, a new five-year strategy and the addition of Birmingham Community Healthcare NHS Foundation Trust as its ninth member.

Professor Lorraine Harper, Managing Director of BHP said: “We are incredibly grateful to Jonathan for his strategic leadership of BHP during a period of substantial change for our organisation, and look forward to continuing to work with him in his new role as Chair of our member HIWM.”

Professor Neil Hanley, Executive Director of BHP and Pro-Vice-Chancellor and Head of the College of Medicine and Health at the University of Birmingham, said: “I would also like to thank Jonathan for his hard work, enthusiasm and friendship over the last couple of years. Jonathan’s appointment to HIWM is a great opportunity to further strengthen relationships and partnerships across the West Midlands, and we are delighted that he will continue to contribute to Birmingham’s health and life sciences in his new role. He has a passion for healthcare innovation that sits at the heart of the Government’s ambitions for the NHS. We will soon begin our search for Jonathan’s successor, a process which will be led by Professor Sir Bruce Keogh.”

Jonathan commented: “I would like to thank the BHP Board, Neil, Lorraine and all the BHP team for their support and their excellent work in leading and reshaping the partnership over the last two years.  I wish BHP ongoing success and I look forward to continuing to work with the partnership in my new role.”

HIWM is one of 15 Health Innovation networks across England, working in partnership with NHS trusts, SMEs, care homes and universities to implement new healthcare and life sciences innovations at scale and pace. By enabling the healthcare system to take advantage of innovations that can help to save time, money and lives, HIWM is working to bring the West Midlands the future of health and social care, today.

Largest ever UK surgical trial aims to reduce post-surgery infections

More than £10m of funding from the National Institute for Health and Care Research (NIHR) has been awarded to BHP founder-member the University of Birmingham to run an ambitious trial which aims to recruit 26,000 patients from 100 sites across the UK in the next five years.

ROSSINI-Platform is a large multi-arm, multi-stage platform trial, led by Professor Thomas Pinkney and the Birmingham Clinical Trials Unit, that will help experts understand how to reduce wound infections that can occur following operations.

Wound infections, also referred to as Surgical Site Infections (SSI), are the commonest complication after surgery and affect up to one in four patients undergoing surgery each year. These infections carry an estimated cost to the NHS of at least £700m each year.

Professor Thomas Pinkney from the School of Health Sciences at the University of Birmingham, and Chief Investigator of the ROSSINI-Platform trial said: “An adult living in the UK will have an average of four operations during their lifetime. Up to a quarter of operations may result in a surgical site infection (SSI) – a post-operative infection of the wound – which can have significant negative impacts on patient recovery.

“We know that infections at different operation sites can cause different types of challenges. For example, an infection following a caesarean section can impact on the mothers’ ability to bond with their newborn. An infection following amputation could mean that the patient is no longer suitable to be fitted for a prosthetic, meaning they might become a wheelchair user.

“Post pandemic the waiting lists for surgeries are higher than ever, so an evidence-based approach to improving recovery times and reducing preventable complications and their associated risk of readmissions has never been more necessary.”

ROSSINI-Platform will look at various interventions to reduce the rates of surgical site infection, and the design of the trial will enable the team to focus on those that show evidence of benefit.

In total, 18 interventions are being assessed in the trial, with examples including:

  • using state-of-the-art wound cleaning solutions during surgery
  • using special wound dressings after surgery,
  • applying antibiotics differently during surgery,
  • changing gloves and instruments at certain points during surgery,
  • waxing or epilation around the surgical site

In addition, the trial will test these interventions across multiple operation types areas such as heart surgery, brain surgery, caesarean section and leg amputation, to find what works best to reduce infection in each setting.

Sue’s story

Sue Blackwell, 49, from Liverpool, has faced health issues over the years connected with inflammatory bowel disease and has had a total of 13 operations. Several operations have resulted in SSIs requiring antibiotics, but one infection led to unexpected complications that impacted Sue’s life for years.

Following a planned completion proctectomy, Sue developed a serious infection leading to being housebound for six months and losing control of her bladder for ten weeks.

Sue had to wait for district nurses to come and change her dressings twice each day, and this had a significant impact on her life. To add to the ordeal, Sue had to undergo additional surgeries to address the complications and experienced problems with wound draining for two years. The seemingly never-ending round of surgeries and treatments continued, and it took a total of eleven years for the wound to fully heal.

Sue is currently doing a PhD at the University of Birmingham and will use her lived experience to inform the ROSSINI-Platform trial as a public involvement representative.

Speaking of her involvement in both developing and delivering the study, Sue said:

“A lot of patients think that someone somewhere along the line is at fault, which isn’t usually the case. SSIs are very common and we don’t know enough about what we can do to stop them. With this trial, all the interventions are already in use, we know they are all safe, we’re just testing them against each other in a smart way, similar to a world cup tournament, to see which comes out on top.”

In addition to delaying or impeding patient recovery, SSIs are responsible for extending hospital stays and hospital readmissions. SSIs are a significant problem for the NHS, due to increased treatment costs and resource usage both in hospital and in the community. SSI is now the most common healthcare associated infection and costs the NHS at least £700million per year. It is therefore a priority for patients and the health service.

The trial team hope that the findings will help countries around the world to implement the most effective ways to prevent SSI following different types of common surgeries. This will help speed up recovery, get patients discharged from hospital sooner freeing up bed space, and in many countries around the world will save countless lives.

You might also be interested in:

Birmingham teenager first in UK to receive groundbreaking diabetes treatment

A young patient identified by the ELSA study as having early stages of Type 1 Diabetes, has received treatment to delay the condition.

Sam, aged 14 and from Kings Norton, was the first to receive the new drug, Teplizumab, at the Clinical Research Facility at Birmingham Children’s Hospital.

Sam’s dad, Chris, has Type 1 diabetes and knowing that family members are more likely to develop the disease, Sam was screened for early stages of the condition and learnt he would develop Type 1 Diabetes. However, there was good news for the family when Sam was offered Teplizumab, a new treatment to delay the onset of the chronic illness. Past trials have proven that Teplizumab delays insulin-dependent diabetes for up to three years.

Sam’s mum, Louise, explained: “I know from Sam’s dad just how stressful life with Type 1 Diabetes is, having to constantly monitor your blood sugar and carry insulin with you at all times. We’re so happy that Sam doesn’t have to worry about his blood sugar yet, especially while he is doing his GCSEs. He can just be a normal teenager.”

Teplizumab is prescribed on a case-by-case basis for children who have been recently diagnosed with type 1 diabetes and are at early stages.

Dr Renuka Dias, a researcher from University of Birmingham’s Department of Applied Health Sciences and Consultant Paediatric Endocrinologist working at Birmingham Women’s and Children’s Hospital, said: “Being able to delay insulin-dependent diabetes will have a huge impact on a child’s life. It means we are letting children have a normal childhood for much longer.”

Dr Dias and her specialist team at the Clinical Research Centre who were involved in Sam’s care have also been integral to a first-of-its-kind study, led by the University of Birmingham, to screen children aged 3 to 13 to find out their risk of developing type 1 diabetes. The study aims to allow treatment to begin sooner and, as in Sam’s case, delay the start of the condition.

The ELSA study has screened over 20,000 children in the UK for Type 1 Diabetes in the last two years. The study is now scaling up throughout Europe.

Unfortunately, it often takes a child becoming seriously unwell for a diagnosis of Type1 Diabetes to be made. Through the study, families identified with a child who is at-risk can begin educating themselves about the condition and learning about the options for management before they find themselves in that crisis situation.

Support and education has been made available to study participants. In addition, some children, like Sam, will be eligible to explore treatment options that could delay the onset of the condition.

Parth Narendran, Professor of Diabetes Medicine at the University of Birmingham and lead for the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital Birmingham (QEHB), said: “We hope that the ELSA study will lead to the roll-out of Type 1 Diabetes early detection programme for children in the UK and that many more children could then benefit from potential treatments to delay Type 1 Diabetes in future.”

Birmingham Women’s and Children’s Hospitals, the University of Birmingham, and University Hospitals Birmingham – which operates QEHB – are founder-members of Birmingham Health Partners. Fellow BHP members Birmingham Community Healthcare NHS Foundation Trust is an ELSA Study partner.

You might also be interested in:

New UK network to strengthen regulatory environment for advanced therapies

A new network has been established to foster collaboration among regulators, industry, and researchers to ensure there is a world-leading regulatory environment in the UK for advanced therapies that supports companies in the development, trial, and launch of these innovative treatments.

The network has been established by the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, and the Birmingham Health Partners Centre for Regulatory Science and Innovation (CRSI), funded by Innovate UK and support from the MHRA.

The effective regulation of advanced therapies is vital to ensure that patients can access these transformative treatments promptly, to prepare the healthcare sector for the large-scale deployment of these therapies, and to ensure patient safety.

To help achieve this, the network will work with the UK regulators, predominately the MHRA, to identify effective and efficient regulatory strategies that address the unique challenges of these therapies. By sharing its recommendations with therapy developers and regulatory and healthcare stakeholders, it will support the UK to build a first-in-class regulatory ecosystem that welcomes and encourages healthcare innovation. This aims to enable the timely development of, and improved access to, safe and effective advanced therapies.

The network is one of seven new Centres of Excellence in Regulatory Science and Innovation established by Innovate UK to help shape the development and approval of medical innovations in the UK.

Matthew Durdy, Chief Executive of the CGT Catapult, said: “Advanced therapies are both an opportunity for patients and an opportunity for the UK. This initiative is part of a drive to keep the UK as a leader in this field.”

Melanie Calvert, Deputy Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for Patient Reported Outcomes Research, Professor of Outcomes Methodology at the University of Birmingham, NIHR Senior Investigator and co-lead of the NIHR Birmingham Biomedical Research Centre’s Patient Reported Outcomes research theme, said: “As the number of advanced therapies requiring regulatory approval increases, it is essential that regulatory frameworks are developed that are fit-for-purpose. Our focus at Birmingham is understanding how the patient voice can help shape regulatory decision making and ensuring that we understand the risks and benefits of treatment from the patient perspective. I am excited to leverage our extensive expertise in the field and work with our partners to provide patients with timely access to transformative treatments.”

You might also be interested in:

Karen Crowdy and Linda Everard named first BHP People award winners

The BHP People award is a new reward and recognition scheme from Birmingham Health Partners, designed to shine a spotlight on our colleagues who play a vital role in the success of clinical trials and research studies, and whose work is integral to groundbreaking scientific endeavours.

By championing individuals including research nurses, statisticians, pharmacists and many others, BHP People also highlights the incredible diversity of careers in research and the essential contributions that these professionals make. As well as celebrating individual excellence, the initiative reflects the shared dedication of our diverse partner organisations to driving collaborative research.

The inaugural BHP People award winners are:

  • Dr Karen Crowdy, Director of Research Strategy and Operations at the Aston Institute of Health and Neurodevelopment (IHN). Karen has been recognised for her outstanding contributions to research delivery, collaboration, training, and culture, as well as her transformative impact on IHN’s growth and success.
  • Linda Everard, R&D Implementation and Performance Manager at Birmingham and Solihull Mental Health NHS Foundation Trust. With a passion for mental health research and service improvement, Linda has been recognised for ensuring that as many service users as possible have access to clinical trials and high-quality research.

Nominating Karen, Aston University’s Professor Claire Farrow, Deputy Dean Research and Enterprise in the College of Health and Life Sciences, said: “As a result of Karen’s work the Institute of Health and Neurodevelopment is thriving. She supports academics to deliver a programme of pioneering research into paediatric conditions such as epilepsy, child brain tumours, and neuro-immunological diseases, leading to the development of personalised interventions that will make a difference to health care professionals, families and children.

“Much of the research that she supports also tackles critical health challenges in the Birmingham area, including respiratory health, child obesity, and diabetes, ensuring research has a direct impact on health inequalities.”

Beyond her strategic influence, Karen understands what makes a great research culture and has spearheaded multiple initiatives to bring together researchers, support early-career researchers, negotiate cotutelle agreements, and stimulate research collaboration and discussion.

Professor Farrow added: “Karen’s creativity combined with exceptional organisation and drive have positioned IHN as a leader in advancing personalised interventions and evidence-based healthcare solutions for children and families. She is a very worthy winner of this award, exemplifying the core values of the BHP People scheme.”

We sat down with Karen to find out a little more about her career journey to date, and how vital cross-organisational collaboration is to research in Birmingham – read her story here: “BHP People – find your niche.

Linda was nominated by BSMHFT’s Head of Research and Development, Emma Patterson, who said: “Without Linda, we quite simply would not be able to run clinical trials. She leads a highly skilled, enthusiastic and motivated team and provides them with opportunities to expand their knowledge and skills by developing their own research.

“She plays a crucial role in training and mentoring the next generation of investigators, supporting new PIs as they take on NIHR portfolio trials and guiding them toward becoming future Chief Investigators. Thanks to her dedication, our research portfolio continues to grow, reaching new clinical areas and broadening opportunities for both staff and service users.

“Beyond her operational impact, Linda is deeply committed to making high-quality research accessible to as many service users as possible. As a co-founder of the Trust’s Lived Experience Action Research (LEAR) Group, she has helped ensure that service users are involved at every stage of research development and delivery. She continues to drive innovation by establishing research champions and engaging underrepresented communities, making her an invaluable force in the advancement of mental health research.”

We met with Linda to find out a little more about her journey from clinical psychology to research delivery, and how she is embedding a culture of research at BSMHFT. Read her story here: BHP People – research is everyone’s business.

The BHP People award will be presented quarterly, focusing on a different pair of member organisations each time.

BHP People – “research is everyone’s business”

Linda Everard, R&D Implementation and Performance Manager at BSMHFT, is one of the is one of the inaugural recipients of the new BHP People Award.

We met with Linda to find out a little more about her journey from clinical psychology to research delivery, and how she is embedding a culture of research in BSMHFT.

Q: Can you briefly run us through your career so far and how you came to work at BSMHFT?

LE: I originally planned to go down the clinical psychology route after completing my undergraduate degree in psychology. I worked in assistant psychologist roles within learning disabilities, CAMHS, and early psychosis, and that’s how I first joined this trust, working half in research and half in a clinical role within psychosis services.

I absolutely loved the research element, and when my boss at the time asked if I wanted to get more involved, I thought, “Why not?” That led me to a research coordinator post in early intervention services, which then developed into programme management. I first managed the DHSC-funded National EDEN Study, and then the NIHR-funded Super EDEN programme in psychosis, which was a turning point for me. Seeing the bigger changes happening in services—sometimes without individuals or even staff realising—made me rethink my career path. I realised I wanted to stay in research rather than pursue clinical psychology.

From there, I moved into programme grant management, and when that project ended, a role came up in R&D managing the delivery team. I got the post in 2015, and now, as Implementation and Performance Manager, I oversee the delivery and governance teams within the R&D department. I absolutely love what I do. It’s incredibly rewarding to see the impact research can have on shaping services and improving care.

Q: What do you think is they key to successfully engaging service users and communities in mental health research?

LE: It can be challenging compared to primary care, where recruitment seems that little bit easier. The key is building strong relationships and trust – not just with service users, but also with our clinical teams who play such a crucial role in connecting us with the right populations.

A lot of our current efforts focus on outreach, particularly within harder to reach communities who perhaps haven’t been involved in any kind of research before. The trust runs engagement events across the patch, and we always make sure the R&D team has a stand and a visible presence at these, providing information and making connections. Transparency and openness are essential, and we actively create spaces for conversation, such as our Lived Experience Action Research (LEAR) Group. This group, made up of service users and carers with an interest in research, helps to promote participation across different settings. Their involvement is invaluable in strengthening engagement and ensuring research is accessible and meaningful to those who need it most.

Q: What role do you see clinical trials playing in advancing mental health care, and how can we ensure they are accessible to diverse groups?

LE: Clinical trials are essential for improving mental health care, but ensuring diverse participation is a challenge we need to address. Something I really want to take forward in the coming years is strengthening engagement with community leaders, whether that’s religious leaders or other trusted figures, because historically this is where we’ve fallen short.

We have an incredibly diverse population here in Birmingham and Solihull, yet many groups aren’t represented well in studies. Some trials, looking at psychosis and schizophrenia in particular, would really benefit from greater diversity and this would lead to more meaningful and applicable findings. To achieve this, we need to enhance our outreach efforts, both within communities and through stronger collaboration with clinical teams.

One positive shift has been the increasing diversity within our own workforce due to expanding our team. Our department is made up of passionate individuals from a variety of backgrounds, cultures and experiences, creating a rich blend of perspectives, skills and ideas. This in turn has allowed us to better understand and address the needs and perspectives of the different populations we serve and will be key to continuing to attract a broader group of participants into clinical research.

Q: Can you talk to us a little more about the research champions you are establishing – what will their role be and what impact do you expect them to have?

LE: We’re still in the early stages, but the goal is to establish two groups of research champions: staff and patients. We want to build a network of people with a genuine interest in research who can act as connectors on the ground. Staff research champions will bring together individuals from different teams to support studies, while patient champions will help recruit participants from various groups and communities.

It’s also about nurturing the researchers of the future. Many doctors coming through need to complete research but have very limited time. By involving them in the research champion programme, we can get them trained, give them a taste of research and recruiting, and show them firsthand how research impacts people’s lives. I think research can be seen as an ‘extra’ rather than an integral part of healthcare, and we want to change that.

Ultimately, we want to embed research into the culture of the trust so that it becomes part of everyday practice, and effectively “everyone’s business”, rather than something only the R&D department handles. There’s still a long way to go, but that’s what makes this job so exciting—there’s always more to be done to drive research forward and make it accessible to everyone.